C Mircea S Tesileanu

8PUBLICATIONS
58CO-AUTHORS
Haematological tumoursPharmacogenomicsEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 03, 2026
Acquired genetic and cell-state changes in IDH-mutant glioma progression.

|Aug 04, 2023
Queries Raised During Oncology Business Pipeline Meetings at the European Medicines Agency: A 5-Year Retrospective Analysis.

C Mircea S Tesileanu, Francesco Pignatti, Enrico Tognana

|May 04, 2023
The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.

C Mircea S Tesileanu, Sotirios Michaleas, Rocio Gonzalo Ruiz

|Aug 16, 2022
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.

Mark P van Opijnen, C Mircea S Tesileanu, Linda Dirven

|Mar 16, 2022
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial.

Kaspar Draaisma, C Mircea S Tesileanu, Iris de Heer

|Mar 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.

C Mircea S Tesileanu, Marc Sanson, Wolfgang Wick

Pageof 2

Frequent Collaborators

4 joint publications

Martin J van den Bent

3 joint publications

Michael Weller

2 joint publications

Wolfgang Wick

2 joint publications

Pim J French